Slides and Webcasts from all ESMO Advanced Courses are reserved to ESMO Members and registered participants, according to the presenters' agreement to release them. ESMO thanks the authors for their generosity.
ESMO Advanced Course on Cholangiocarcinoma 2024: Madrid
- Start date
- 25 Oct 2024
- End date
- 26 Oct 2024
- Location
- Madrid, Spain
Learning objectives
- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease
Co-Chairs
- Julien Edeline, France
- Angela Lamarca, Spain
Travel grant
In addition to the course registration and the hotel accommodation, a travel grant of maximum 600 euros is offered to non-local participants as a contribution versus their travel costs (excluding Visa costs).
Participants must supply proof of travel as appropriate (tickets and receipts/invoices).
The reimbursement will be processed after the course according to the rules below:
Distance |
Reimbursement per return trip |
|---|---|
Up to 100 km |
EUR 70.00 |
101 > 399 km |
EUR 150.00 |
> 400 km |
Please visit this page and use the rail or flight calculator by inserting the city of departure and the city of arrival; then refer to Table 2 (on the same page) to check the reimbursement amount corresponding to the calculated distance. |
*Place of work | |
Accreditation
The programme of this event has been accredited with 10 ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. Recertification guarantees that a certified medical oncologist has continued to update her/his knowledge and continues to possess the necessary skills and standards for the practice of medical oncology. For further details, please refer to ESMO-MORA Recertification Process & Requirements.
Supported by
